Clinical Trial Update: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

Phase 2 study of MEDI8968 for moderate-to-severe hidradenitis suppurativa was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• MEDI8968

Snippet

Sponsor: AstraZeneca | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: TERMINATED | Results posted: 2016-09-01